Giant cell arteritis (GCA) is an autoimmune disease marked by inflammation of blood vessels in the head and neck, leading to persistent headaches, flu-like symptoms, and risk of blindness. The most common treatment for GCA is a high-dose corticosteroid, typically started immediately after diagnosis to reduce the risk of blindness and tapered off over the next 12-24 months. In 2017, the first targeted treatment for GCA, Roche’s Actemra, was approved. Other key autoimmune drugs, including Novartis’s Cosentyx, AbbVie’s Rinvoq, and Regeneron / Sanofi’s Kevzara, are progressing to late-phase trials for GCA, suggesting increasing interest in this potentially lucrative and untapped market. As such, understanding how Actemra is currently used in GCA patients will be crucial for incoming competition.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Release date: August 2020
Geography: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Actemra, corticosteroids, DMARDs, immunosuppressants
Key analysis provided: Brand / therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, and product-level patient flowcharts.